

Spectrum Physician's Orders Health NATALIZUMAB (T NATALIZUMAB (TYSABRI) -**ADULT, OUTPATIENT, INFUSION CENTER**

Page 1 of 3

Patient Name
DOB
MRN
Physician
FIN

Anticipated Infusion Da	iteICD 1	10 Code with Descrip	tion	
Height	(cm) Weight	(kg) Allergies		
Provider Specialty				
☐ Allergy/Immunology	☐ Infectious Dis	sease	□ OB/GYN	□ Rheumatology
□ Cardiology	☐ Internal Med	Family Practice	□ Other	□ Surgery
☐ Gastroenterology	□ Nephrology		☐ Otolaryngology	□ Urology
☐ Genetics	□ Neurology		□ Pulmonary	☐ Wound Care
Site of Service				
☐ SH Gerber	☐ SH Lemmen	Holton (GR)	□ SH Pennock	☐ SH United Memorial
☐ SH Helen DeVos (GI	R)	า	☐ SH Reed City	☐ SH Zeeland
Treatment intent				
□ Conditioning	□ Curative		☐ Mobilization	□ Supportive
☐ Control	☐ Maintenance		□ Palliative	

Cycle	1	# of cycles	:	Cycle length: 28 days	
	Day 1				Perform every 1 day x1
	Appo	intment Requests			
		ONCBCN CALCULATE	D LENGTH INFUSION		
		APPOINTMENT REQU	EST 1		
		Interval:	Occurrences:		
		ONCBCN ADMIT APPO	INTMENT REQUEST		
		Interval:	Occurrences:		
	Safet	y Parameters and Special Inst	ructions		
	Gaiot	ONO DAFETY BABANI			
		INSTRUCTIONS 6			
		Interval: Until	Occurrences:		
		discontinued			
		Comments:	NATALIZUMAB (TYSAB	RI) - The REMS progra	am requires that a
			Medication Guide be disp		
				fda.gov/drugsatfda_do	cs/label/2017/1215104s9
			59lbl.pdf#page=30		
			The prescriber (or infusion	on nurse) will complete	the Pre-Infusion Patient
			Checklist with each patie		
			within 1 business day of		
			For more information: htt		m.com/TTP/
			Purpose:		
			To increase awareness of		
			leukoencephalopathy (Pl		
			increased risk with longe		
			use, and the presence of		
			warn against concurrent		
			5 5	•	promised patients; and to

PML is suspected.

CONTINUED ON PAGE 2 →



Spectrum NATALIZUMAB (TYSABRI) -ADULT, OUTPATIENT, **INFUSION CENTER** (CONTINUED)

Page 2 of 3

Patient Name
DOB
MRN
Physician

Ρ	r۸۱	/ıd	er	к	em	inc	1er

ONC PROVIDER REMINDER 28

Interval: Once Occurrences: --

Order MRI Brain once per year. Comments:

In reference to increasing the risk of PML consider 3 known risk factors:

- Treatment periods beyond 2 years
- Prior treatment with immunosuppressants

FIN

Presence of JVC antibodies.

Labs

HEPATIC FUNCTION PANEL

Interval: --Occurrences: --

Note: Natalizumab should be discontinued in patients with Jaundice or other laboratory evidence of substantial liver injury.

Labs

STRATIFY JCV ANTIBODY (WITH INDEX) W/REFLEX TO INHIBITION ASSAY

Interval: --Occurrences: --

Nursing Orders

ONC NURSING COMMUNICATION

Interval: Until Occurrences: discontinued

Treatment Parameters

ONC MONITORING AND HOLD PARAMETERS Occurrences: --Interval:--

Comments:

Premedications

Premedications (include dose, frequency, and timing in relation to chemotherapy): Interval: Occurrences: --

Comments:

Vitals

VITAL SIGNS

Interval: PRN Occurrences: --

Comments: Take vital signs at initiation and completion of infusion and as frequently

as indicated by patient's symptoms.



Spectrum NATALIZUMAB (TYSABRI) -**ADULT, OUTPATIENT, INFUSION CENTER** (CONTINUED)

Page 3 of 3

Patient Name
DOB
MRN
Physician

FIN

NΛ	20	lica	atir	٦n

natalizumab (TYSABRI) 300 mg in sodium chloride 0.9 % 115 mL IVPB

Dose: 300 mg Route: Intravenous Once over 1 Hours for 1 dose

Start: S End: S

Instructions:

Patients should be closely monitored for signs and symptoms of hypersensitivity during the infusion and for at least 1 hour after the infusion is complete. The infusion should be discontinued if a reaction occurs, and treatment of the reaction should be instituted. Following infusion, flush line with 0.9% NS.

Selected Adds Vol. Ingredients: Name Type Dose

> **NATALIZUMAB 300** Medications 300 mg Main Yes MG/15ML IV CONC Ingredient SODIUM CHLORIDE Base 100 mL Always

Yes

0.9 % IV SOLN Must only be diluted in 0.9% sodium chloride-do not shake

Medications

sodium chloride 0.9% bolus injection 100 mL

Dose: 100 mL Route: Intravenous Once for 1 dose

Start: S End: S

Instructions:

To mix with natalizumab when patient supplies

Telephone order/Verbal order documented and read-back completed. Practitioner's initials

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED: VALIDA		VALIDATED:	VALIDATED:				
	TIME	DATE	TIME	DATE	TIME	DATE	Pager #
		Sign		R.N. Sign		Physician Print	Physician

EPIC VERSION DATE: